Chardan Capital Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $21

Benzinga | Jan 8, 2021 4:55 AM EST

Chardan Capital Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $21

Chardan Capital analyst Geulah Livshits initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target of $21.